Evidence mapPaperPMID 34495393Full record

ReviewCurrent diabetes reports2021

Metformin in Pregnancy for Women with Type 2 Diabetes: a Review.

Jamie L Benham, Lois E Donovan, Jennifer M Yamamoto

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jamie L BenhamDepartment of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Lois E DonovanDepartment of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Jennifer M YamamotoDepartment of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. jennifer.yamamoto@umanitoba.ca.
University of Calgary · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo review the current evidence for the use of metformin in pregnancy for women with type 2 diabetes. RECENT

findingsA large, multicenter, double-blind randomized controlled trial found that women with type 2 diabetes in pregnancy treated with metformin as an adjunct to insulin therapy had less gestational weight gain, insulin requirements, caesarian sections, macrosomia, and neonatal adiposity, but more neonates were small for gestational age (SGA) compared with insulin alone. It is unclear if the higher number of SGA infants are a direct result of metformin exposure or mediated through other effects such as less gestational weight gain and improved glycemic control. Additional follow-up studies of offspring exposed to metformin in utero are required. Metformin may be a useful adjunctive treatment for women with type 2 diabetes in pregnancy to help meet glycemic targets if there are no concerns for or indications of SGA.

Indexed as

Diabetes, GestationalDiabetes Mellitus, Type 2MetforminBlood GlucoseFemaleHumansHypoglycemic AgentsInsulinMulticenter Studies as TopicPregnancyRandomized Controlled Trials as TopicBlood GlucoseHypoglycemic AgentsInsulinMetforminDiabetes mellitusMetforminPregnancytype 2Women’s health

Identifiers

PMID34495393
OpenAlexW3196338801

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.